[PDF][PDF] Double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacologic effect of CP-690,550 in patients with psoriasis
MG Boy, C Wang, BE Wilkinson, VFS Chow… - The journal of …, 2009 - academia.edu
MG Boy, C Wang, BE Wilkinson, VFS Chow, AT Clucas, JG Krueger, AS Gaweco…
The journal of investigative dermatology, 2009•academia.edu(JAK3) in T cells is expected to uncouple early T-cell receptor-triggered signaling from
downstream events (Pesu et al 2005) and, for this reason, JAK3 inhibitors could be effective
in T-cell-mediated disorders such as psoriasis. CP-690,550 is an orally active highly
selective JAK inhibitor and Abbreviations: AE, adverse events; bid, two times-daily dosing;
IL, interleukin; JAK, Janus kinase; K16, keratin 16; LSM, least squares mean; PGA,
Physician's Global Assessment (of Psoriasis); PLSS, Psoriatic Lesion Severity Sum; qd …
downstream events (Pesu et al 2005) and, for this reason, JAK3 inhibitors could be effective
in T-cell-mediated disorders such as psoriasis. CP-690,550 is an orally active highly
selective JAK inhibitor and Abbreviations: AE, adverse events; bid, two times-daily dosing;
IL, interleukin; JAK, Janus kinase; K16, keratin 16; LSM, least squares mean; PGA,
Physician's Global Assessment (of Psoriasis); PLSS, Psoriatic Lesion Severity Sum; qd …
(JAK3) in T cells is expected to uncouple early T-cell receptor-triggered signaling from downstream events (Pesu et al 2005) and, for this reason, JAK3 inhibitors could be effective in T-cell-mediated disorders such as psoriasis. CP-690,550 is an orally active highly selective JAK inhibitor and
Abbreviations: AE, adverse events; bid, two times-daily dosing; IL, interleukin; JAK, Janus kinase; K16, keratin 16; LSM, least squares mean; PGA, Physician’s Global Assessment (of Psoriasis); PLSS, Psoriatic Lesion Severity Sum; qd, once-daily dosing; SD, standard deviation; SE, standard error www. jidonline. org 2299
academia.edu